SM04554 Phase II
An important bit of news surfaced online this weekend about the company Samumed and their heralded phase 2 results. Samumed will be presenting “Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial” on March 5th, 2016 at the 74th Annual Meeting of the American Academy…
Read More